KRMD

Business Context and Reporting Period

Company: Repro-Med Systems, Inc. (Note: Metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: November 30, 2008
Business Overview: The Company researches, develops, and markets medical devices, primarily the Freedom60 Syringe Infusion System and the RES-Q-VAC Emergency Airway Suction System. It is classified as a smaller reporting company.

Key Financial Metrics

Profit Margins: Management notes a profit margin increase from 62% to 63% for the nine-month period due to production efficiencies.
Debt: Total debt includes a $379,065 note to a financial institution and $427,421 in long-term debt (including related party loans).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 37% for the three months ended Nov 30, 2008, and 53% for the nine-month period compared to the prior year.
• Profitability Turnaround: The Company reported a net income of $535,460 for the nine months ended Nov 30, 2008, compared to a net loss of $65,791 in the same period in 2007. This represents a total improvement of $601,251.
• Product Performance:
  • Freedom60: Sales increased 66% (quarterly) and 87% (nine-month) driven by Medicare reimbursement clarifications for subcutaneous immune globulin (SCIG).
  • RES-Q-VAC: Sales decreased 17% in the quarter but increased 16% for the nine-month period.
• Expense Management: Interest expense decreased 52% quarterly and significantly year-to-date due to paying off high-interest demand notes. Research and Development expenses decreased due to resource reallocation to sales.
• Liquidity: Cash provided by operating activities turned positive ($310,716) compared to a cash outflow of $20,075 in the prior year.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects sales and cash flow to continue increasing, particularly in the SCIG market. They believe current capital is sufficient to meet financial needs for the next twelve months.
• Government Grant: The Company received approval for a $150,000 grant from the Trade Adjustment Assistance Program, which matches company spending 50-50 on marketing, ISO, regulatory affairs, and R&D.
• Risks:
  • Reimbursement: Reliance on Medicare reimbursement policies; changes could adversely affect sales.
  • Competition: Potential entry of lower-cost competitors, particularly for the RES-Q-VAC line.
  • Regulatory: Uncertainty regarding FDA regulations and government approvals.
  • Tax Contingency: The Company has a net operating loss carryover of ~$2.8 million and did not file income taxes for four fiscal years. Management acknowledges a "more likely than not" probability of tax penalties, though the specific amount cannot be determined.
• Contingencies: A provision of approximately $62,000 has been recorded for a contractual commitment to rework a product for a customer.

Investor Verification Checklist

• Revenue Concentration: Verify the extent of reliance on the Freedom60 product line and the stability of the specific Medicare HCPCS code (E0779) reimbursement.
• Tax Liability: Confirm the status of the unfiled tax returns and any correspondence with taxing authorities regarding potential penalties and interest.
• Related Party Transactions: Review the terms of the $100,000 loan from the President and the $294,000 loan from a Director, including interest rates and maturity dates.
• Grant Utilization: Verify the drawdown and matching requirements of the $150,000 Trade Adjustment Assistance grant.
• Debt Covenants: Assess the terms of the $379,065 revolving loan from the financial institution, specifically regarding the "due on demand" clause.